AbbVie Dermatology QSP Platform: Build Strategy and Applications in Psoriasis Drug Discovery and Clinical Development
by Oliver Ghobrial, Sr. Scientist III Systems Pharmacology/DMPK/PKPD, AbbVie, Inc. April 13, 2016 12:00 - 1:00 pm EDT Abstract: In immune disease, complex interactions between predisposing genetics, the inflammatory network, and the tissue parenchyma are thought to play a role in disease pathogenesis. QSP provides a framework to integrate these correlations and uncover the precise combination and sequence of mechanisms responsible for disease. A psoriasis (Ps) QSP platform was developed to describe the homeostatic interactions between the skin dynamics, and the immune system in health and disease. This QSP platform enables a quantitative predictive understanding for the role of predisposing genetics and cause of disease (vs. downstream consequence of disease), value of novel therapies, responder/non-responder subpopulations to them, and the signature biomarker patterns to identify these subpopulations. The virtual patient, virtual cohort, and virtual population, development strategies will be presented and utility of this approach to explore competing hypotheses of Ps pathophysiology will be demonstrated. Register at http://rosaandco.com/webinarGhobrial.html
